OMER Cantor Fitzgerald upgraded Omeros to Overweight from Neutral with a $22 price target. The left the company's Q2 report with the belief that Yartemlea is having a much better than expected launch. After talking to physicians, Cantor is "increasingly convinced" Yartemlea can be a bigger drug than it appreciated. Physician feedback has been largely positive, pointing to 30%-40% market share over time, the analyst tells investors in a research note. Cantor upped its peak sales estimate to $400M